Substituted [1,4]oxazino[2,3-g]indazoles for the treatment...

Details Substituted [1,4]oxazino[2,3-g]indazoles for the treatment... Substituted [1,4]oxazino[2,3-g]indazoles for the treatment...

2007-09-11

2007-09-11

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S229800, C544S099000

Reexamination Certificate

active

11180186

ABSTRACT:
Substituted [1,4]oxazino[2,3-g]indazols for lowering intraocular pressure and treating glaucoma are disclosed.

REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5290781 (1994-03-01), Espino et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5494928 (1996-02-01), Bös
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 5561150 (1996-10-01), Wichmann
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5578612 (1996-11-01), Macor et al.
patent: 5646173 (1997-07-01), Bös et al.
patent: 5652272 (1997-07-01), Ogawa et al.
patent: 5693654 (1997-12-01), Birch
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6245796 (2001-06-01), Maeno et al.
patent: 6518294 (2003-02-01), Teng et al.
patent: 6660870 (2003-12-01), Ruskinko et al.
patent: 6664286 (2003-12-01), May et al.
patent: 6696476 (2004-02-01), Chen et al.
patent: 6806285 (2004-10-01), May et al.
patent: 2003/0083346 (2003-05-01), May et al.
patent: 2003/0181503 (2003-09-01), May et al.
patent: 0 771 563 (2003-01-01), None
patent: WO 92/00338 (1992-01-01), None
patent: WO 94/03162 (1994-02-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 97/35579 (1997-10-01), None
patent: WO 98/18458 (1998-05-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 99/59499 (1999-11-01), None
patent: WO 00/12475 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44753 (2000-08-01), None
patent: WO 00/77002 (2000-12-01), None
patent: WO 00/77010 (2000-12-01), None
patent: WO 01/12602 (2001-02-01), None
patent: WO 01/40183 (2001-06-01), None
patent: WO 01/70207 (2001-09-01), None
patent: WO 01/070222 (2001-09-01), None
patent: WO 01/70223 (2001-09-01), None
patent: WO 01/70230 (2001-09-01), None
patent: WO 01/70701 (2001-09-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 01/70745 (2001-09-01), None
patent: WO 01/85152 (2001-11-01), None
patent: WO 03/051291 (2002-06-01), None
patent: WO 03/051352 (2002-06-01), None
patent: WO 03/053436 (2002-07-01), None
patent: WO 02/098350 (2002-12-01), None
patent: WO 02/098400 (2002-12-01), None
patent: WO 02/098860 (2002-12-01), None
patent: WO 01/83487 (2003-07-01), None
patent: WO 03/101379 (2003-12-01), None
patent: WO 2004/019874 (2004-03-01), None
patent: WO 2004/028451 (2004-04-01), None
patent: WO 2004/054572 (2004-07-01), None
patent: WO 2004/058725 (2004-07-01), None
Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.
Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.
West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 358.
Uchikawa, et al., Synthesis of a Novel Series of Tricyclic Indan Derivatives as Melatonin Receptor Agonists, J. Med. Chem. 45, 4222-4239 (2002).
Bowen et al. “Nonlinear regression using spreadsheets,”Trends in Pharmacological Sciences, vol. 16, pp. 413-417 (1995).
Chang et al., “Mechanism of the Ocular Hypotensive Action of Ketanserin,”J. of Ocular Pharmacology, vol. 1(2), pp. 137-147 (1985).
Fiorella et al., “Role of 5-HT2Aand 5-HT2Creceptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives,”Psycopharmacology, vol. 121, pp. 357-363 (1995).
Gupta et al., “Therapeutic Potentials of 5-HT Receptor Modulators,”Indian J. of Pharmacology, vol. 26, pp. 94-107 (1994).
Johnson et al., “Binding to the Serotonin 5-HT2Receptor by the Enantiomers of 125I-DOI,”Neuropharmacology, vol. 26(12), pp. 1803-1806 (1987).
Krootila et al., “Effect of Serotonin and Its Antagonist (Ketanserin) on Intraocular Pressure in the Rabbit,”J. of Ocular Pharmacology, vol. 3(4), pp. 279-290 (1987).
Mallorga et al., “Characterization of Serotonin Receptors in the Iris + ciliary body of the albino rabbit,”Current Eye Research, vol. 6(3), pp. 527-532 (1987).
Mano et al., “The Effect of Anplag (Sarpogelate HCL), New Selective 5-HT2Antagonist on Intraocular Pressure in Rabbits,”IOVS, vol. 36(4), S719 (1995).
May et al., “A Novel and Selective 5-HT2Receptor Agonist with Ocular Hypotensive Activity: (S)-(+)-1-(2-Aminopropyl)-8,9-dihydropyrano[3,2-e]indole,”J. Med. Chem., vol. 46, pp. 4188-4195 (2003).
May et al., “Evaluation of the Ocular Hypotensive Response of Serotonin 5-HT1Aand 5-HT2Receptor Ligands in Conscous Ocular Hypertensive Cynomolgus Monkeys,”J. of Pharmacology and Experimental Therapeutics, vol. 306(1), pp. 301-309 (2003).
Osborne et al., “Do Beta-Adrenoceptors and Serotonin 5-HT1AReceptors Have Similar Fumctions in the Control of Intraocular Pressure in the Rabbit,”Ophthalmologica, vol. 210, pp. 308-314 (1996).
Osborne et al., “5-Hydroxytryptamine1Aagoists: potential use in glaucoma. Evicence from animal studies,”Eye, vol. 14(38), pp. 454-463 (2000).
Takeda et al., “The Effect of Inplag. Novel Selective 5-HT2Atagonist on Intraocular Pressure in Glaucoma Patients,”IOVS, Vo. 36(4), S734 (1995).
Wang et al., “Effect of 5-methylurapidil, an α1a-adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits,”Current Eye Research, vol. 16, pp. 769-775 (1997).
Wang et al., “Effect ofp-MPPI Hydrochloride (p-MPPI) applied before 5-Methylurapidil (5-MU) on Intraocular Pressure (IOP) in Normal Monkeys,”IOVS, vol. 39(4), S488 (1998).

Affiliated with

Also associated with

Rating

Substituted [1,4]oxazino[2,3-g]indazoles for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted [1,4]oxazino[2,3-g]indazoles for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted [1,4]oxazino[2,3-g]indazoles for the treatment... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3793956